Ionis Launches Phase 3 Trial of Donidalorsen for Preventing Attacks

Ionis Launches Phase 3 Trial of Donidalorsen for Preventing Attacks

312572

Ionis Launches Phase 3 Trial of Donidalorsen for Preventing Attacks

Ionis Pharmaceuticals has launched a registrational Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational therapy donidalorsen, formerly known as IONIS-PKK-LRx, in people with hereditary angioedema (HAE) types 1 and 2. While the trial, called OASIS-HAE, may already be recruiting, information on recruitment status and locations is not yet available. Should the trial’s findings be positive, Ionis plans to use them to support applications seeking the therapy’s approval. “Initiating the Phase…

You must be logged in to read/download the full post.